Bypassing the Endothelial Vessel Requirement
Traditional models of tumor vascularization rely on angiogenesis—the process where a tumor secretes signaling molecules to recruit and sprout host endothelial cells, building a network of blood vessels to sustain its growth. Because tumors depend heavily on this nutrient supply, modern oncology has focused on anti-angiogenic therapies designed to disrupt these pathways. However, aggressive tumors frequently develop resistance to these treatments, continuing to grow and metastasize even when traditional vessel recruitment is completely blocked.
How do they bypass this restriction? Instead of relying on host endothelial cells, highly malignant tumor cells leverage their own cellular plasticity to physically reshape themselves into functional, fluid-conducting channels. This autonomous microcirculation network acts as a backup perfusion system. By lining these makeshift conduits themselves, tumor cells establish a continuous nutrient supply and create a direct pipeline into the systemic circulation, significantly increasing the risk of metastasis.
Cellular Plasticity and the Shape-Shifting Mechanism
To construct a fluid-conducting channel without endothelial cells, a tumor cell must undergo a profound phenotypic transformation. This capability is not uniform across the entire tumor mass; rather, it is highly concentrated within a subpopulation of aggressive, stem-like cells known as tumor-initiating cells (TICs) or cancer stem cells.
As demonstrated by Yanhui Zhang et al. in Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells, cells grown in 3D spheroids become enriched with TICs that possess the specific plasticity required to differentiate into endothelial-like cells. This structural remodeling is intimately tied to the epithelial-mesenchymal transition (EMT). During EMT, tightly bound epithelial tumor cells shed their rigid architectural constraints, adopt a flexible, mobile mesenchymal phenotype, and gain the ability to organize into hollow, matrix-rich conduits. This process allows the tumor to build its own plumbing from the inside out, utilizing its own cellular building blocks to mimic traditional vasculature.
The Paradox of Therapy-Induced Vascular Remodeling
One of the most critical insights into this non-endothelial vascular network is that conventional cancer therapies can paradoxically accelerate its formation. When clinicians deploy anti-angiogenic drugs or standard chemotherapies to starve a tumor, they induce severe localized hypoxia (oxygen deprivation). Instead of shutting down the tumor, this extreme environmental stress acts as a master switch that forces the tumor into an aggressive survival mode.
This survival program is heavily mediated by the upregulation of the hypoxia-inducible factor-1α (HIF-1α) pathway. For example, Min Su et al. established in Involvement of human chorionic gonadotropin in regulating vasculogenic mimicry and hypoxia-inducible factor-1α expression in ovarian cancer cells that upstream signaling molecules like human chorionic gonadotropin (hCG) can drive the transformation of ovarian cancer cells into vessel-like networks via HIF-1α activation.
When traditional vessels are stripped away, the tumor responds by rapidly accelerating its autonomous channel construction. Danfang Zhang et al. documented this phenomenon in Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer, showing that the anti-angiogenic drug sunitinib triggers the expression of the transcription factor Twist1. This expands the population of CD133+ cancer stem cells, driving the rapid assembly of alternative fluid channels.
Similarly, Chen Wang et al. noted in Telangiectatic osteosarcoma of the thoracic vertebra: a case report and literature review that standard cytotoxic chemotherapy can inadvertently promote these non-angiogenic fluid channels, facilitating the survival and expansion of treatment-resistant clones.
Molecular Architects of Autonomous Networks
The assembly of these non-endothelial channels requires precise coordination between intracellular transcription factors, systemic signaling axes, and the surrounding extracellular matrix.
- Transcriptional and Epigenetic Control: The structural remodeling of tumor cells is tightly governed by specific epigenetic modifiers. Kai Zeng et al. demonstrated in USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma how the enzyme USP22 stabilizes the transcription factor ZEB1 to alter the tumor's expression profile, facilitating the phenotypic transition required for vascular remodeling.
- Systemic and Microenvironmental Signaling: Beyond localized hypoxia, broader systemic pathways can fuel this process. As reviewed by Yan Wang et al. in Renin-angiotensin-system and clear cell renal carcinoma: research advances and future perspectives, the renin-angiotensin system can actively promote the organization of aggressive cancer cells into fluid-conducting channels. Furthermore, tumors can alter their wider microenvironment to support these networks; for instance, Qiuyun Li et al. in The Tumor Microenvironment Remodeled by Epstein–Barr Virus: From Primary Site to Distant Metastatic Niche highlighted how viral factors can reshape the microenvironment to favor non-endothelial vessel structures.
- Extracellular Matrix Assembly: For tumor cells to form stable, hollow pipes, they must interact dynamically with the extracellular matrix. Victor Oginga Oria et al. showed in Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma that the cooperation between fibromodulin (FMOD) and the stemness marker SOX2 is required for melanoma cells to organize into vascular-like structures. Silencing these factors collapses the physical architecture of the alternative network.
Importantly, these autonomous networks frequently operate alongside other non-traditional vascularization pathways. Tumors can sustain growth through hypoxia-independent mechanisms, such as the BACH1-dependent pathway identified by Ting Wang et al. in Antioxidants stimulate BACH1-dependent tumor angiogenesis, or by utilizing stem cells to drive endothelial growth via alternative growth factors like bFGF rather than VEGF, as detailed by Zhangsheng Xiong et al. in IFITM3 promotes glioblastoma stem cell-mediated angiogenesis via regulating JAK/STAT3/bFGF signaling pathway.
Therapeutic Strategies to Collapse Alternative Networks
Because these non-endothelial channels provide a critical escape route that drives the metastatic process—a connection highlighted in circulating tumor cell analyses by Srujana S. Yadavalli et al. in Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells—finding ways to target and collapse them is essential for overcoming treatment resistance.
One strategy involves targeting the metabolic and molecular checkpoints that allow tumor cells to maintain this high degree of plasticity. Manda Sun outlines in Research Progress on the Function of Chk2 Protein how the Chk2 protein acts as a central signal distributor that can suppress non-angiogenic vascularization, particularly in p53-mutant cancers, making it a valuable checkpoint for therapeutic exploration.
Another approach focuses on multi-targeted interventions that can simultaneously disrupt the overlapping signaling cascades driving EMT and hypoxia responses. For example, Fenggang Hou et al. demonstrated in Yi Ai Fang, a traditional Chinese herbal formula, impacts the vasculogenic mimicry formation of human colorectal cancer through HIF-1α and epithelial mesenchymal transition that the traditional Chinese herbal formula Yi Ai Fang (YAF) can suppress the formation of these alternative networks in colorectal cancer by concurrently inhibiting the HIF-1α and EMT pathways.
By shifting the therapeutic focus from merely blocking endothelial sprouting to actively preventing tumor cell shape-shifting, researchers aim to eliminate the alternative circulatory networks that allow aggressive cancers to survive standard treatments.
Key Foundational Work
Yi Ai Fang, a traditional Chinese herbal formula, impacts the vasculogenic mimicry formation of human colorectal cancer through HIF-1α and epithelial mesenchymal transition (2016) — contributed 3 concept elements to this direction.
Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer (2014) — contributed 2 concept elements to this direction.
Spheres derived from the human SN12C renal cell carcinoma cell line are enriched in tumor initiating cells (2016) — contributed 1 concept elements to this direction.